PURPOSE. The purpose of this study was to establish the mutation spectrum of an Usher type I cohort of 61 patients from France and to describe a diagnostic strategy, including a strategy for estimating the pathogenicity of sequence changes. METHODS. To optimize the identification of Usher (USH)-causative mutations, taking into account the genetic heterogeneity, preliminary haplotyping at the five USH1 loci was performed to prioritize the gene to be sequenced, as previously described. Coding exons and flanking intronic sequences were sequenced and, where necessary, semiquantitative PCR and multiplex ligation-dependent probe amplification (MLPA) were performed to detect large genomic rearrangements.
U sher syndrome refers to recessively inherited disorders with associated hearing loss (HL), retinitis pigmentosa (RP), and, sometimes, vestibular dysfunction. Three clinical subtypes, USH1, -2, and -3, are defined with respect to the degree and progression of HL and the presence or absence of vestibular areflexia. Usher syndrome type I (USH1) is the most disabling form and is characterized by congenital and profound HL and vestibular dysfunction. RP develops progressively, with night blindness and restriction of the visual field as the first symptoms, as is also true in the other two subtypes. Five causative genes have been identified for USH1 (MIM 276900), myosin VIIA (MYO7A; MIM 276903), harmonin (USH1C, MIM, 605242), cadherin 23 (CDH23, MIM 605516), protocadherin 15 (PCDH15, MIM 605514), and SANS (USH1G, MIM 607696), involved in USH1B (MIM 276900), USH1C (MIM 276904), USH1D (MIM 601067), USH1F (MIM 602083), and USH1G (MIM 606943), respectively. At least two additional genes, lying at loci USH1E (MIM 602097) and USH1H (MIM 612632), remain to be characterized. 1, 2 The prevalence of all combined types of Usher syndrome has been long estimated to be 1 in 25,000 in studies from the United States and Scandinavia, but recent studies estimate an incidence of 1 in 6000. 3 Identifying pathogenic USH1 mutations remains laborious, as it is impossible to select a gene to be analyzed on the basis of the symptoms and most likely pathogenic variants remain private or rare (see LOVD-USHbases; https://grenada.lumc. nl/LOVD2/Usher_montpellier/USHbases.html/ provided by the Usher Group, Montpellier, France), with the exception of a few mutations that are more prevalent in specific populations because of founder effects. A genotyping microarray has been developed by Asper Ophthalmics (Tartu, Estonia), 4 but the sensitivity is estimated to be 0.5, 3 leaving numerous unsolved diagnostic cases with either both or a single mutation undetected. Our group developed a strategy that includes preliminary haplotype analysis before sequencing of the candidate gene(s) 5 that has been since upgraded with a systematic multistep analysis involving new technological developments and interpretative tools.
We present, in this study, data obtained after 4 years of USH1 molecular studies using this approach. Seventy-eight USH1 mutations were identified among 61 patients, and 32% of them are newly described here. Together with our previous work, we found that 92 USH1 patients carried mutations in a USH1 gene. We emphasize several factors that are crucial for a proper diagnostic service.
PATIENTS AND METHODS

Patients
Patients were referred from medical genetic clinics and ophthalmology and ENT services distributed throughout France. In addition four patients were referred from medical genetics clinics in Italy and the United Kingdom.
The parents were available in 70% of the cases. All patients had audiograms, fundus examination (FE), and/or electroretinograms (ERGs), with the exception of one (patient U379-1). Usher type 1 was diagnosed on the basis of congenital profound sensorineural deafness, vestibular dysfunction, and retinal degeneration. The degree of RP varied among the patients.
This study was approved by the local Ethics Committee and was conducted in accordance with the Declaration of Helsinki. Informed consent for genetic testing was obtained from adult probands or parents, in the case of minors, after explanation of the nature of the study and its possible implications to patients and families.
Patients were mainly Caucasian, but were also North African, Guinean, and Pakistani.
Molecular Analyses
Haplotyping at the five USH1 loci (USH1B, USH1D, USH1F, USH1C, and USH1G) and sequencing analyses of the five USH1 genes (MYO7A, CDH23, PCDH15, USH1C, and USH1G) have been described. 5 Several approaches have been used to characterize the large genomic rearrangements: (1) semiquantitative assays were performed by quantitative multiplex PCR of short fluorescent fragments (QMPSF) and semiquantitative nonfluorescent multiplex PCR 6 adapted to MYO7A gene rearrangements; (2) multiplex ligation-dependent probe amplification (MLPA) has been designed by MRC-Holland (Amsterdam, The Netherlands) for the PCDH15 gene. This kit (SALSA MLPA kit 292-A1 PCDH15; MRC-Holland) was used according to the manufacturer's recommendations to detect PCDH15 rearrangements; (3) a CGH-microarray chip (12 ϫ 135k), laboratory designed and including the Usher genes, was used on a high-resolution microarray platform according to the manufacturer's recommendations (Nimblegen; Roche Diagnostics, Basel, Switzerland) and allowed the identification of the CDH23 exon 20 duplication. The CGH-microarray chip includes 49,144 probes covering all Usher genes (except CLRN1) and their 10,000-bp 5Ј and 3Ј regions. The average probe length is 60 bases. The average spacing between starts of the overlapping probes (inner spacing) covering the exons and their 100-bp intronic borders is 10 bp, and spacing between the adjacent probes (outer-spacing) covering the introns and the 5Ј and 3Ј regions is 40 bp.
In Silico Studies
Software used to predict potential splicing alterations has been detailed previously. 7, 8 The multistep analysis for determining the pre-dicted effect of alteration of a variant on protein structure has been described. 9 The National Center for Biotechnology (NCBI) RefSeq IDs were MYO7A, 4647; CDH23, 64072 (with the initiation codon located in exon 1); PCDH15, 65217; USH1C, 10083; and USH1G, 124590 (available at www.ncbi.nlm.nih.gov/locuslink/refseq/ NCBI, Bethesda MD).
RESULTS
Haplotype Analyses
Haplotype analyses were systematically performed to prioritize the gene to be sequenced. If several sibs were available, one or more loci could be excluded by a simple linkage approach. Haplotypes were also useful in simplex cases to look for homozygosity at a locus. 5 Homozygosity for one locus was revealed in 18 families, and the corresponding gene was sequenced, allowing the identification of the homozygous pathogenic genotype in all cases (12 for MYO7A, 3 for CDH23, 2 for PCDH15, and 1 for USH1C; Table 1 ). At least one locus could be excluded in an additional six cases (U649, U773, U909, U439, U331, U468, and U322; haplotype analyses not shown). Therefore, similar to our previous data, haplotyping proved its usefulness in 44% (25/59 families) of the cases.
Mutation Analysis
Seventy-eight mutations and likely pathogenic variants are reported in the USH1 genes in Table 2 . Twenty-five of them are newly identified. Together with our previous report 5 a total of 58 (48ϩ10) different mutations have been identified in MYO7A, 28 (19ϩ 9) in CDH23, 16 (7ϩ 9) in PCDH15, and 6 (3ϩ3) in USH1C. Mutations are of all types and include premature termination codons (PTCs) due to nucleotide substitutions, small deletions or insertions, missense and translationally silent substitutions (exonic synonymous changes and intronic variations), large genomic rearrangements (that involve at least one-exon), and in-frame deletions. Mutations leading to PTCs or involving large rearrangements are deemed a priori to be deleterious. Any new translationally silent (synonymous) substitution or missense change is considered initially to be an unclassified variant (UV) or a variant of unknown clinical significance and therefore requires special attention to assess its potential pathogenic effect before categorizing it, or not, as likely to be pathogenic (UV3). The multistep analysis, presented in Figure 1 , takes into account the clinical and biological context, potential alteration of pre-mRNA splicing, and, when appropriate, the potential effect on the native protein structure and conformation.
Summary of Mutations
The MYO7A gene shows the highest rate, 36% (21/58), of nucleotide substitutions leading to missense (Table 2) . Indeed, three so-called missense variants were predicted to alter normal splicing of pre-mRNA-p.Ala198Thr, p.Gly1982Arg, and p.Lys400Asn, confirmed in the first two cases by minigene analysis. 5, 7 They are not considered missense changes. CDH23 contains the highest rate, 30% (8/28), of splicing alterations (Table 3 ). In addition, half the USH1C mutations (3/6) result in aberrant splicing. Some remove the canonical AG/GT sites, but some also lie in the introns, outside the invariant sites, or correspond to exonic nucleotide substitutions. Ex vivo assays and transcript analyses from nasal cells for CDH23 c.6050 -9GϾA and ex vivo assays for USH1C c.1210ϩ6TϾC provided evidence for deleterious outcomes with the creation of PTC, either by use of a created acceptor site 8, 25 in the first case or by activation of an upstream exonic cryptic splice site in the 
Gene
Family Genotype
U379 family consists of the two parents (U379 -1 and U379 -2) and 1 child (U379 -3) with different phenotypes and was therefore considered for calculations as a single family but 3 patients. U653A and U653B were referred as a couple and were therefore considered as two families for calculations.
* Families already reported in Blanchet et al. 10 † Mutations carried by these patients were included in Baux et al. 11 Genotypes are presented according to HGVS nomenclature. Therefore, when segregation analysis could not be performed the uncertain status is indicated with (ϩ). latter. 7 The USH1C c.216GϾA variant was previously shown to be an in-frame 29 or an out-of-frame 31 splice site mutation. Of note, nasal epithelial cell analyses of U819 revealed the simultaneous presence of both effects. Finally, our data confirm that PCDH15 is particularly prone to large rearrangements, as they represent 37% (6/16) of the mutations. The presence of large genomic rearrangements is considered in all cases when either no mutation in any of the five USH1 has been detected, or a single mutation at the UV3 level has been identified in one of the USH1 genes.
Assessment of the Pathogenic Effect of the Missense Alterations
Several lines of evidence (see Fig. 1 ) are used to classify the UVs. 5, 9 Table 2 includes only variants that have been classified as likely to be pathogenic (i.e., corresponding to UV3 and UV4, according to the CMGS guidelines (url: http://www.cmgs.org/ provided by the Clinical Molecular Genetics Society, a subsidiary body of the British Society for Human Genetics), with the exception of the MYO7A F1346del variant classified as UV2, mainly because it has been characterized in a complex allele, together with the deleterious p.Cys1198X mutation (patient U811; Table 1 ).
Analyses at the protein level are performed according to a multistep process (Fig. 1 ). The steps have been combined as a new tool dedicated to missense in Usher genes, USMA (Usher Syndrome Missense Analysis, currently in beta version for public use, available at https://194.167. 35 .160/cgi-bin/USMA/USMA. fcgi).
DISCUSSION
Diagnostic Approach
Together with published studies from our laboratory, [5] [6] [7] [8] 10, 11 we provide evidence of a powerful service for patients. A total of 92 patients have received diagnoses, with no ambiguous USH1 genotypes.
These 4 years of service confirm that the chosen approach (i.e., preliminary haplotyping before gene sequencing) is efficient, as it helped in 44% of the families to prioritize the gene to be sequenced. For example, this strategy proved to be efficient for U819. As homozygosity was found at the USH1C locus, only USH1C was sequenced to identify the homozygous causative mutation. For uninformative families, the genes were sequenced following their relative involvement. This effort was laborious and time consuming for U360, as MYO7A, CDH23, and PCDH15 had to be sequenced before identifying the pathogenic USH1C genotype. The finding of homozygosity was frequently useful, even in cases without any indication of consanguinity. Interestingly, this empiric finding has recently been used to identify a new retinal-renal ciliopathy gene. 32 The spectrum of mutations is notable for the high proportion of private mutations. Twenty-five are reported here for the first time (i.e., 32%). To these, an additional 18 private variants can be added that were published separately by our group in the course of the creation of USHbases, ex vivo assays and nasal cell transcript studies. 7, 8, 11 Only a few founder effects have been observed-for example the CDH23 p.Arg1502X mutation in Swedes, 26 PCDH15 p.Arg245X in Ashkenazi Jews, and USH1C c.216GϾA in Acadians 29, 30 and Quebecois. 33 As a consequence the Asper chip based on known mutations would have been inefficient and would have solved only 52% of the cases. The calculation includes the data presented in Roux et al. 5 * Premature stop codons (PTCs) due to nucleotide substitution and small deletions and insertions.
† Splicing defects predicted or demonstrated by ex vivo splicing assays (minigenes) and/or transcripts studies from nasal epithelial cells.
New technologies allowing large scale sequencing of exomes 32, 34 will become available to diagnostic services as costs reduce further, probably in the comparatively near future. Preliminary capture of the 5 USH1 genes, including intronic sequences, should be fairly straightforward. As well as simple technical problems (difficulty of finding genome rearrangements, or small del/ins) the results will elicit issues of interpretation. On the positive side they will produce evidence for some complex genotypes that may be related to variable phenotypes thus providing clues to overlapping phenotypes (socalled atypical Usher). They will also reveal probably rare digenic cases, as has been recently shown in USH2 with the GPR98 and PDZD7 genes. 35 They will also generate high amounts of data that will complicate the interpretation of the results and the message to the families.
It is also clearly demonstrated with the data presented here and previously 5 that, an efficient diagnostic service must include approaches other than sequencing, such as MLPA, QMPSF, or array-CGH, this is particularly crucial for PCDH15, but also for MYO7A.
The service must also have access to tools for proper interpretation of the different variants identified in the course of the analysis. These tools require expertise in bioinformatics. In diagnostics, consideration of the splicing effect of translationally silent or missense alterations is crucial for correct classification of gene alterations. 7, 36, 37 Numerous splicing prediction software programs are available and have been reviewed by Spurdle et al. 38 Although useful, the outcome of the splicing default is still difficult to predict, and ex vivo assays and splicing studies from RNA are therefore preferable.
We compile the maximum information available for a given variant (orthologue analysis, alignment of protein domains, secondary structure, and 3D predictions), which we consider to be more informative than a predictor program, as many are heavily based on alignments. 39 We designed software to fulfill our needs, called USMA (Baux D, unpublished, 2010, see the Results section). Another benefit of customized assessment is that sometimes it is possible to envisage the molecular mechanism responsible for protein function and pathogenicity.
Complex Genotypes and Phenotypes
Family U379 had undergone several investigations, as the father (U379-1) was diagnosed with congenital profound deafness and the mother (U379-2) with mild-to-severe deafness and late RP, fortuitously diagnosed at the age of 24. However, the daughter (U379-3) had typical USHI signs (profound deafness, vestibular areflexia, and RP onset at the age of 12). In view of the variety of symptoms, several types of transmission had been hypothesized, including dominant and mitochondrial inheritance. When the family was referred to our laboratory, we considered the known involvement of some Usher genes in NSHL as well as variable clinical manifestations and decided to screen the MYO7A gene. The genotypes proved to be quite challenging to interpret. The p.Thr165Ala mutation was identified for the first time in this patient. Residue Thr165 has been implicated as a recessive mutation (p.Thr165Met). It is part of the ATP binding cluster GESGAGKT[EV] of the myosin VIIA protein (Fig. 2) 40 which is particularly conserved among myosins. 41 All variants identified at positions 163 to 165 (residues GKT) are considered to act as recessive alterations (see below; LOVD-USHbases). It was therefore logical to regard p.Thr165Ala as a likely pathogenic recessive alteration.
The clinical variability in this family is not clearly understood. The father (U379-1) suffers from NSHL, although no additional ophthalmic exploration could be performed to exclude the RP phenotype, but he did not complain of night blindness or restricted visual fields at the age of 56. The common cause of NSHL by DFNB1 mutations was excluded, as well as the presence of the mitochondrial A1555G change. He carries the MYO7A genotype p.
[Gly1159Val]ϩ[Gln1798X]. The mother, presenting with atypical USH1, carries p.Thr165Ala in trans to c.3502CϾT (p.Arg1168Trp). Interestingly, the neighboring substitution c.3503GϾC (predicted p.Arg1168Pro) 12 has been shown to be acting at splicing level, as it induces the skipping of exon 27, whereas c.3502CϾT does not. 7 Therefore, any likely pathogenic effect is due to the Arg to Trp change. Using our standard techniques, we have no explanation for why both parents display a milder phenotype, and this is consistent with the clinical variability of MYO7A mutations previously observed. 24, 42 
Patient U189
This young patient was referred with diagnosed clinical USH1, presenting with particularly early ophthalmic symptoms. Nystagmus at the age of 3 months and abnormal ERG led to the diagnosis of RP at the age of 1 year. The child also had some balance problems, but walked at 18 months. Profound deafness was diagnosed at 3 years. Molecular analysis found two CDH23 deleterious mutations. During USH2A c.2299delG random screening in USH patients and controls for epidemiologic studies to establish the carrier frequency, 9 a c.2299delG mutation was revealed in the patient that was inherited from the mother. Perhaps USH2A acts as a modifier of the RP phenotype in this patient on a CDH23 background, similarly to what has been recently demonstrated for PDZD7 acting as a modifier on a USH2A background. 35 The mother was double heterozygous for CDH23 c.6146_6153del and USH2A c.2299delG. Unfortunately, additional clinical explorations could not be performed in the mother, but she had no apparent Usher-linked symptoms.
The practical use of our diagnostic service was shown for couple U653A and U653B. Both patients, affected with typical USH1, wanted to know their risk of having an affected child. Both of them carried two deleterious mutations in the MYO7A gene, leading to unambiguous genetic counseling.
Patient U331
Patient U331 (typical USH1) was referred with two nonaffected siblings. Linkage analysis at the different USH loci excluded MYO7A. All the other USH1 genes were sequenced, and a single deleterious mutation in PCDH15 (deletion of exons 18 -26) was found. We also excluded mutations in CLRN1, involved in USH3, known to overlap with USH1 phenotype. Recently additional alternative spliced exons have been identified, 43 and their analysis revealed a new missense alteration (NM_001142769.1:c.4853AϾC, NP_001136241.1: p.Glu1618Ala, in exon 38 of isoform CD2.1) allelic to the E18-26 deletion. It is likely that a second PCDH15 alteration remains undetectable, lying in unscreened regions (i.e., located deep in the introns or in the regulatory regions or because of allele dropout [due to an SNP located on one of the used primers that is not described in SNP databases]). Digenism cannot be excluded; PCDH15/CDH23 digenic inheritance has been documented, 44 but that was before the awareness that large rearrangements in PCDH15 were involved in a non-negligible proportion. 6, 45 CDH23 has been sequenced in the course of the study, and no pathogenic mutation or UV could be identified. Unfortunately, this family still has a partial genotype, and additional investigations are necessary.
USHbases
All the USH1 alterations presented in this study were incorporated into the USHbases, as well as all likely nonpathogenic and neutral variants found among the patients. These databases, previously using the UMD software, 11 have recently been updated using the LOVD open-source system. They are now available at https://grenada.lumc.nl/LOVD2/Usher_montpellier/USHbases.html, and databases for WHRN and GPR98 have been added.
Thanks to this study, the database number of pathogenic variants has been raised from 189 to 201 for MYO7A and from 352 to 377 for the five USH1 genes.
Use of databases is becoming crucial in diagnosis for pooling data and sorting genotypes and for interpretation. By integrating all the records into databases, this study shows once more the powerful source of data that diagnostic services can offer, not only to the patients and their families but also to the scientific community and other diagnostic laboratories.
Contribution of the USH Genes/Overall Mutation Detection Rate
Among the 31 USH1 families previously published and the 59 reported in this study, MYO7A was implicated in 63.3%, CDH23 in 20%, PCDH15 in 12.2%, and USH1C in 4.5%. MYO7A was predominant, but one in three cases involved one cadherin gene. USH1C was only rarely involved in our cohort, whereas we have never identified any pathogenic variants in USH1G.
Overall, the mutation detection rate was greater than 90%. Of the few patients in whom we were unable to establish a molecular cause, at least some had an atypical phenotype.
